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 Abstract
Background: The role of CYP1A1, CYP1B1 and CYP3A4 polymorphism in pathogenesis of breast cancer has not 
been fully elucidated. From three CYP1A1 polymorphisms *2A (3801T>C), *2C (2455A>G), and *2B variant, which 
harbors both polymorphisms, the *2A variant is potentially carcinogenic in African Americans and the Taiwanese, 
but not in Caucasians, and the CYP1B1*2 (355G>T) and CYP1B1*3 (4326C>G) variants might increase breast 
cancer risk. Although no association of any CYP3A4 polymorphisms and breast cancer has been documented, the 
CYP3A4*1B (392A>G) variant, correlates with earlier menarche and endometrial cancer secondary to tamoxifen 
therapy.
Objective: The present study was designed to investigate the frequency of CYP1A1, CYP1B1 and CYP3A4 po-
lymorphisms in a sample of breast cancer patients from the Polish population and to correlate the results with the 
clinical and laboratory findings.
Material and methods: The frequencies of CYP1A1*2A; CYP1A1*2C; CYP1B1*3; CYP3A4*1B CYP3A4*2 
polymorphisms were determined in 71 patients aged 36-87, with primary breast cancer and 100 healthy indi-
viduals. Genomic DNA was extracted from the tumor, and individual gene fragments were PCR-amplified. The 
polymorphisms were determined by RFLP and were correlated with the patients’ TNM stage, grade, estrogen and 
progesterone receptor status as well as the level of c-erbB-2 protein.
Results: CYP1A1 polymorphisms were more frequent in younger patients and in the patients with high level of c 
erbB 2 protein. No correlation between these polymorphisms and the cancer stage or grade, as well as the receptor 
status was demonstrated.
Conclusions: CYP1A1 polymorphisms probably predispose to an earlier onset of breast cancer and might be as-
sociated with higher c-erbB-2 protein level, but further studies on a much larger group are required to substantiate 
our findings.
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Introduction
	 The	 CYP1A1, CYP1B1 and CYP3A4 gene	 products,	
cytochromes	P4501A1,	P4501B1	and	P4503A4,	play	an	important	
role	in	the	metabolism	of	both	natural	and	environmental	estrogens.	
Numerous	polymorphisms	of	 these	genes	have	been	described,	
but	 it	 is	not	clear	whether	 they	affect	 the	enzymatic	activity	of	
cytochromes	 or	 correlate	 with	 breast	 cancer.	 Several	CYP1A1 
polymorphisms	were	described.	The	CYP1A1*2A	(3801T>C)	is	
localized	in	the	region	encoding	the	3’UTR	and	the	CYP1A1*2C 
variant	 (2455A>G),	 situated	 in	 exon	 7,	 causes	 Ile462Val	
substitution	 in	 the	 heme-binding	 domain	 of	 cytochrome	 P450	
1A1,	 while	 CYP1A1*2B	 variant	 harbors	 both	 polymorphisms	
[1,	 2].	 It	 has	 been	 shown,	 that	CYP1A1*2A	 is	 associated	with	
increased	 risk	 of	 breast	 cancer	 in	African	Americans	 and	 the	
Taiwanese	[3-5],	but	not	in	Caucasians	[6].
	 The	CYP1B1*2	(355G>T)	variant,	causing	Ala119Ser	change	
and	CYP1B1*3	(4326C>G)	causing	Leu432Val	substitution	[7],	
result	in	increased	4-hydroxylation	of	E1	[8,	9]	and	hence	might	
increase	the	risk	of	breast	cancer	[10-12].
It	is	not	known	whether	the	CYP3A4*2 (15713T>C)	polymorphism	
localized	 in	 exon	 7,	 causing	 Ser222Pro	 substitution,	 and	
CYP3A4*3	variant	 (1437T>C)	situated	 in	exon	12,	 resulting	 in	
Met455Thr	substitution,	affect	the	16-hydroxylase	activity	[13].	
To	 date,	 no	 association	 of	 any	 CYP3A4	 polymorphisms	 with	
breast	cancer	has	been	documented	[14].	However,	CYP3A4*1B 
(392A>G)	 variant,	 localized	 within	 the	 nifedipine	 response	
element,	 coincided	 with	 early	 menarche	 [15]	 and	 endometrial	
cancer	secondary	to	tamoxifen	therapy	[16].
	 Present	study	was	designed	to	investigate	the	frequency	of	
CYP1A1,	CYP1B1 and	CYP3A4 polymorphisms	in	breast	cancer	
patients	in	the	sample	of	Polish	population	and	to	associate	these	
polymorphisms	with	the	onset	of	the	disease	as	well	as	the	cancer	
stage,	grade	and	the	receptor	status.
Material and methods
Patients
	 In	 this	study,	71	patients	 (aged	36-87,	with	a	medium	age	
of	58.1)	with	primary	breast	cancer	diagnosed	in	the	Department	
of	Clinical	Oncology	at	Poznan	University	of	Medical	Sciences,	
were	 enrolled.	 Clinical	 characteristics,	 including	 TNM	 stage,	
grade,	expression	of	estrogen	and	progesterone	receptors	in	tumor	
tissue	and	 family	history,	were	obtained	 from	medical	 records.	
Samples	of	breast	cancer	tissue	(1cm3)	were	collected	from	every	
patient	and	frozen	for	further	analysis.	A	100	pregnant	patients	
(aged	23-42,	with	a	medium	age	of	28.2)	from	the	Department	
of	Gynecology	and	Obstetrics	at	Poznan	University	of	Medical	
Sciences,	devoid	of	any	symptoms	of	breast	cancer,	served	as	the	
control	group.	The	local	Ethics	Committee	approved	the	project,	
and	a	written	consent	from	each	patient	was	obtained.
Methods
	 The	 DNA	 was	 isolated	 from	 breast	 cancer	 tissue,	 while	
peripheral	 blood	DNA	was	 isolated	 from	 the	 control	 subjects.	
Amplification	 of	 individual	 gene	 fragments	 was	 conducted	 by	
PCR	with	the	use	of	specific	primers	as	previously	described	[6,	
13,	17-19].	The	polymorphisms	were	detected	by	RFLP	analysis	
with	the	use	of	the	appropriate	restriction	endonucleases	(MspI	
for	CYP1A1*2A;	NcoI	for	CYP1A1*2C;	Eco57I	for	CYP1B1*3; 
MboII	for	CYP3A4*1B	and	XcmI	for	CYP3A4*2). The	levels	of	
ER	 and	 PR	 proteins	 in	 breast	 cancer	 tissue	were	 evaluated	 by	
immunohistochemistry	 with	 the	 use	 of	 monoclonal	 antibodies	
(DakoCytomation,	 Denmark),	 while	 C-erbB2	 protein	 level	
was	 estimated	 with	 the	 use	 of	 HercepTest	 (DakoCytomation,	
Denmark)	according	to	the	producer’s	instructions.
	 The	frequencies	of	genotypes	were	established	with	the	use	
of	Arlequin	2.001	software,	while	Hardy-Weinberg’s	Equilibrium	
(HWE)	was	determined	with	the	use	of	hwe.exe	software.	Both	
 Streszczenie
Wstęp: Rola polimorfizmów genów CYP1A1, CYP1B1 oraz CYP3A4 w patogenezie  raka piersi nie została w pełni 
wyjaśniona. Spośród trzech polimorfizmów CYP1A1*2A (3801T>C), *2C (2455A>G), oraz *2B, który zawiera oba 
warianty, tylko wariant *2A jest potencjalnie rakotwórczy u afro-amerykanów i mieszkańców Tajwanu, ale nie u rasy 
kaukaskiej, natomiast polimorfizmy CYP1B1*2 (355G>T) i CYP1B1*3 (4326C>G) mogą zwiększać ryzyko rozwoju 
raka piersi. Chociaż nie stwierdzono związku żadnego z polimorfizmów CYP3A z rakiem piersi, dowiedziono, że wa-
riant CYP3A4*1B (392A>G) współistnieje z wcześniejszym występowaniem miesiączki oraz rakiem endometrium 
w następstwie leczenia tamoksyfenem. 
Cel: Celem badań było oznaczenie częstości występowania polimorfizmów CYP1A1, CYP1B1 i CYP3A4 w grupie 
chorych z rakiem piersi z populacji polskiej oraz poszukiwanie korelacji  z wynikami badań klinicznych i laborato-
ryjnych.
Materiał i metody: Częstości polimorfizmów CYP1A1*2A; CYP1A1*2C; CYP1B1*3; CYP3A4*1B i CYP3A4*2 
oznaczono u 71 chorych (w wieku 36-87 lat) oraz 100 zdrowych kobiet. Genomowy DNA wyekstrahowano z tkanki 
guza i fragmenty poszczególnych genów amplifikowano za pomocą PCR. Polimorfizmy wykrywano techniką RFLP 
i korelowano ich występowanie ze stopniem zaawansowania klinicznego i histologicznego nowotworu, obecnością 
receptorów estrogenów i progesteronu jak również poziomem białka c-erbB-2.
Wyniki: Polimorfizmy CYP1A1 częściej występowały u młodszych chorych oraz u chorych z wysokim poziomem 
białka c-erbB-2. Nie wykazano korelacji pomiędzy obecnością polimorfizmów a stopniem zaawansowania nowo-
tworu czy obecnością receptorów.
Wnioski: Polimorfizmy CYP1A1 przypuszczalnie predysponują do wcześniejszego występowania raka piersi 
i mogą wiązać się z podwyższeniem poziomu białka c-erbB-2, lecz potwierdzenie tych spostrzeżeń wymaga dal-
szych badań w większych grupach pacjentów.
 Słowa kluczowe: rak piersi / CYP1A1 / CYP1B1 / CYP3A4 / polimorfizmy genetyczne / 
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were	 verified	 with	 Fisher	 exact	 test.	 The	 correlation	 between	
genotypes	 and	 age	 of	 disease	 onset,	 cancer	 stage,	 grade	 and	
expression	of	ER	and	PR	were	measured	using	gamma	coefficient	
and	 Fisher	 exact	 test.	 The	 significance	 of	 the	 differences	 was	
tested	at	the	level	of	p<0.05.
Results and discussion
	 Frequencies	of	all	CYP	polymorphisms,	except	CYP1B1*3 
and	 CYP3A4*1B,	 were	 consistent	 with	 Hardy-Weinberg	
Equilibrium	 (HWE).	 The	 inconsistency	 of	 CYP1B1*3	 with	
HWE	 resulted	 from	higher	 frequency	 of	 the	 polymorphic	 than	
the	 wild-type	 variant.	 Since	CYP1B1*3	 variant,	 in	 contrast	 to	
the	 rest	of	 the	world,	was	 rare	 in	Caucasians,	 it	was	called	 the	
“wild	type”.	This	was	the	reason	why	it	was	less	frequent	than	
the	“polymorphic”	variant,	which	resulted	in	inconsistency	with	
HWE.	 The	 distribution	 of	 CYP3A4*2	 was	 inconsistent	 with	
HWE	 because	 no	 patients	 with	 the	 variant	 allele	 were	 found.	
Since	frequency	of	this	variant	in	the	general	population	is	about	
2.7%	[13],	the	study	group	was	too	small	to	identify	carriers	of	
this	polymorphism.
	 Although	an	increased	risk	of	breast	cancer	in	the	patients	
harboring	 the	 CYP1A1*2A	 polymorphism	 was	 observed	 in	
African	Americans	 and	 the	Taiwanese	 [3-5,	 20],	 the	 results	 of	
metaanalysis	 [4]	 showed	 that	 CYP1A1*2A	 and	 CYP1A1*2C 
polymorphisms	 did	 not	 increase	 the	 risk	 of	 breast	 cancer.	Our	
results	(Table	1)	were	similar	to	those	reported	in	Caucasians	[18,	
21-23],and	were	consistent	with	the	data	from	metaanalyses	[21,	
22].
	 Significantly	 higher	 (p>0.003)	 frequency	 of	 CYP1A1 
polymorphisms	was	 found	 in	 pre-menopausal	 (below	 50	 years	
of	age)	 than	in	postmenopausal	(over	50	years	of	age)	women,	
strongly	 suggesting	 an	 association	 between	 the	 polymorphic	
alleles	and	breast	cancer	onset.	(Figure	2).	
	 Similar	association	concerning	CYP1A1*2A	and	CYP1B1*3 
variants,	was	described	by	Han	et al. [11],	who	suggested	 that	
the	polymorphisms	of	both	genes	 resulted	 in	 an	 early	onset	 of	
the	disease.	Based	on	our	results,	we	postulate	that	the	original	
observation	 of	 Han	 et al.	 might	 apply	 at	 least	 to	 all	CYP1A1 
polymorphisms,	but	further	investigation	on	a	much	larger	cohort	
is	necessary	to	confirm	this	hypothesis.
	 We	 found	 that	 the	 frequency	 of CYP1A1*2A	 allele	 in	 the	
investigated	 group	was	 slightly	 lower	 (6%)	 than	 that	 obtained	
in	 other	 studies	 made	 in	 Caucasian	 population,	 including	
metaanalyses	[21,	24,	25].	All	patients	participating	in	our	study	
originated	 from	 the	western	part	of	 the	 country	and	 this	might	
be	 the	 reason	why	 the	 allele	distribution	 resembled	 that	 of	 the	
German	population	and	differed	from	other	European	ones.
	 It	 was	 reported	 that	 CYP1B1	 polymorphism	 might	 be	 a	
sensitive	marker	of	breast	cancer	[26].	Our	results	were	consistent	
with	metaanalysis	[27]	and	did	not	reveal	any	difference	in	the	
frequency	 of	 CYP1B1*3	 allele	 between	 the	 patients	 and	 the	
healthy	controls.
	 Although	there	were	no	reports	of	 the	correlation	between	
CYP3A4	polymorphisms	and	breast	cancer,	it	was	shown	that	the	
breast	cancer	patients	harboring	CYP3A4*1B	polymorphism	and	
treated	with	tamoxifen,	more	often	developed	endometrial	cancer	
[16].	
 
Figure 1. Restriction fragment length polymorphism (RFLP) analysis of CYP 
polymorphisms.
(A) CYP1A1*2A. (+), positive control (fragment of pS2 digested with MspI); 
(-), negative control (undigested fragment of the same amplicon), M, size marker. (B) 
CYP1A1*2C. (+), positive control (fragment of ERβ digested with NcoI); 
(-), negative control (undigested fragment of the same amplicon); M, size marker. 
(C) CYP1B1*3. (+), positive control (fragment of C-erbB-2 digested with Eco57I); (-), 
negative control (undigested fragment of the same amplicon); M, size marker. (D) 
CYP3A4*1B. (+), positive control (fragment of ERβ digested with Mbo II); 
(-), negative control (undigested fragment of the same amplicon); M, size marker. 
(E) CYP3A4*2. (+), positive control (fragment of ERβ digested with XcmI); 
(-), negative control (undigested fragment of the same amplicon); M, size marker; 
H2O, negative control of PCR.
.
Nr 11/2009822
P R A C E  O R Y G I N A L N E
  g in eko l og ia
Ociepa-Zawal	M,	et	al.
Ginekol Pol. 2009, 80, 819-823
	 The	presence	of	CYP3A4*1B	and	CYP3A5*3 polymorphisms	
in	 some	patients	might	 also	 influence	 the	metabolism	of	drugs	
used	 in	 chemotherapy	 and	 thus	 exacerbate	 the	 prognosis	 [28,	
29].	However,	 in	 our	 study	we	 did	 not	 find	 any	 effects	 of	 the	
investigated	polymorphisms	on	survival	 rate	during	nearly	 two	
years	of	observation.
	 In	accordance	with	earlier	studies	[4],	we	found	no	correlation	
between	the	presence	of	any	polymorphic	CYP allele	and	breast	
cancer	stage	or	grade	as	well	as	 the	ER	or	PR	status	and	other	
breast	cancer	risk	factors	(smoking,	obesity	and	family	history).	
Only	 in	 the	 Chinese	 population,	 the	 presence	 of	CYP1A1	 and	
CYP1B1	variants	were	found	to	exacerbate	the	prognosis	[30].
Our	preliminary	findings	on	the	content	of	oncogenic	C-erbB-2	
protein	 in	 the	 breast	 cancer	 tissue,	 in	 the	 patients	 harboring	
CYP1A1 polymorphisms, revealed	 higher	 levels	 in	 carriers	
of	 CYP1A1	 polymorphisms	 (not	 shown).	 The	 C-erbB-2	 gene	
encodes	a	membrane	receptor	homologous	to	the	EGF	receptor	
[31],	which	forms	dimers	with	the	C-erbB-3	receptor,	resulting	in	
stimulation	of	cell	division	[32].	Overexpression	of	the	C-erbB-2 
can	 thus	 constitute	 an	 independent	 negative	 prognostic	 factor	
in	 breast	 cancer.	 Since	 it	was	 shown,	 that	 the	most	 aggressive	
form	of	the	disease	was	found	in	patients	with	the	higher	level	of	
C-erbB-2	protein	[33],	it	is	possible	that	the	incidence	of	CYP1A1 
and	 CYP1B1	 polymorphisms	 associated	 with	 high	 levels	 of	
C-erbB-2	protein	might	thus	exacerbate	the	prognosis.
	 Although	our	results	suggested	an	association	between	the	
CYP1A1 polymorphisms	and		earlier	breast	cancer	onset,	recent	
studies	[34],	which	showed		that	the	variant	alleles	might	interact,	
indicate	 that	 the	 role	 of	 polymorphisms	of	 the	 genes	 encoding	
estrogen	 metabolizing	 enzymes	 in	 breast	 cancer	 needs	 further	
investigation	requiring	large	cohorts	of	patients. Acknowledgements
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M. Lacinski in statistical analysis and editorial assistance 
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Table I. Distribution of polymorphic alleles in the investigated groups. 
 
Figure 2. The association between CYP1A1 polymorphisms and the age of onset 
of breast cancer. 
Patients were divided into two groups: below and over 50 years of age and the 
statistical analysis of the incidence of polymorphisms was conducted as described in 
Materials and Methods section.  
0 – no CYP1A1 polymorphisms; 1 – one polymorphism; 2 – two polymorphisms.
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